Effect of trimethoprim-sulphamethoxazole in Langerhans' cell histiocytosis: preliminary observations

Med Pediatr Oncol. 1995 Aug;25(2):74-8. doi: 10.1002/mpo.2950250205.

Abstract

Twenty-three children with Langerhans' cell histiocytosis (LCH) have been treated with trimethoprim-sulphamethoxazole (T-S) in a 4-year period. The children are classified in two main groups according to the extent of their disease. Group A includes 16 children with single system disease and group B, seven children with multisystem disease. All patients were treated for 4 weeks to 3 months. The results of treatment are evaluated in terms of response in individual organs involved. All children with single system disease had a good response to the drug. Children with multisystem disease had a good response to some organs but a poorer outcome for the lungs and for the blood. These patients did not respond even to conventional chemotherapy.

Publication types

  • Clinical Trial

MeSH terms

  • Child
  • Child, Preschool
  • Female
  • Histiocytosis, Langerhans-Cell / diagnostic imaging
  • Histiocytosis, Langerhans-Cell / drug therapy*
  • Histiocytosis, Langerhans-Cell / pathology
  • Humans
  • Infant
  • Male
  • Parotid Gland / diagnostic imaging
  • Radiography
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use*

Substances

  • Trimethoprim, Sulfamethoxazole Drug Combination